2017-11-15T06:36:34-06:00 2016-12-31 BDO USA LLP 8401 GREENSBORO DRIVE 800 MCLEAN VA 22102 990 2016-01-01 522044704 AERAS % DONNA D'AMATO AERA 3015472900 1405 RESEARCH BLVD Suite 300 ROCKVILLE MD 20850 DANIEL REZNIKOV CFO 7038930600 2017-10-18 true Jeffrey J Schragg P00234543 7038930600 24.75.238.77 54621820173195000001 2017-11-15 P 96D23D8D7C8A9AC89CF3E23BB654D763CAA7DBF9 2767BCF7E269D2D3434BA551614CF79CF55D6980 2016 2017-02-10 21:41:12Z JACQUELINE SHEA LUCAS 1405 RESEARCH BLVD ROCKVILLE MD 20850 36040897 false X WWW.AERAS.ORG X 1997 DC DEDICATED TO THE DEVELOPMENT OF EFFECTIVE TUBERCULOSIS (TB) VACCINES & BIOLOGICS TO PREVENT TB ACROSS ALL AGE GROUPS IN AN AFFORDABLE & SUSTAINABLE MANNER. 11 10 87 10 0 37195632 33389937 2257095 347985 2323144 14736 -2495831 -1299400 39280040 32453258 500000 2308237 0 0 15916104 11456275 0 0 0 34903488 20715513 51319592 34480025 -12039552 -2026767 32649234 28445760 8262934 6175785 24386300 22269975 X AERAS IS A NON-PROFIT PRODUCT DEVELOPMENT ORGANIZATION DEDICATED TO THE DEVELOPMENT OF EFFECTIVE TUBERCULOSIS (TB) VACCINES AND BIOLOGICS TO PREVENT TB ACROSS ALL AGE GROUPS IN AN AFFORDABLE AND SUSTAINABLE MANNER. AERAS UTILIZES ITS BROAD CAPABILITIES AND TECHNOLOGIES IN COLLABORATION WITH NUMEROUS PARTNERS AND STAKEHOLDERS TO SUPPORT THE DEVELOPMENT OF VACCINES AND OTHER BIOPHARMACEUTICALS TO ADDRESS TB AND OTHER SIGNIFICANT PUBLIC HEALTH NEEDS OF UNDERSERVED POPULATIONS. IN THE PURSUIT OF OUR MISSION, WE ARE GUIDED BY OUR CORE VALUES. THESE CORE VALUES EXPRESS OUR ASPIRATIONS AND THE BEHAVIORS WE WANT TO EXHIBIT AND MODEL. THEY SHAPE THE CULTURE AND CHARACTER OF AERAS AND INFORM ALL OF OUR DECISIONS AND ACTIONS. false false 13018353 PRECLINICAL - AERAS DEVELOPS AND ASSESSES A RANGE OF VACCINE PLATFORMS AND VARIATIONS, AND EXPLORES NOVEL APPROACHES TO ENHANCE THE EFFECTIVENESS OF NEW TB VACCINES IN EFFECTIVE PRIME-BOOST REGIMENS. AERAS EVALUATES TB VACCINE CANDIDATES TO DETERMINE WHETHER THEY HAVE THE CHARACTERISTICS NEEDED TO MOVE FORWARD TO THE NEXT PHASE OF DEVELOPMENT. KEY ELEMENTS INCLUDE EVALUATION OF SAFETY, IMMUNOGENICITY AND THE PROTECTION THE CANDIDATES PROVIDE IN ANIMAL MODELS. AN INDEPENDENT PANEL OF VACCINE EXPERTS EVALUATES ALL RELEVANT PRECLINICAL DATA BEFORE A CANDIDATE IS APPROVED FOR ENTRY INTO PHASE I TRIALS. AERAS ALSO SUPPORTS THE ASSESSMENT OF NOVEL ASSAYS THAT COULD BE IMPLEMENTED AT THE CLINICAL STAGE OF DEVELOPMENT TO DRASTICALLY REDUCE THE TIME AND COST OF DEVELOPING NEW VACCINES AGAINST TUBERCULOSIS. 13892691 2308237 CLINICAL - AERAS AND ITS RESEARCH PARTNERS HAVE TRANSFORMED THE TB VACCINE CLINICAL LANDSCAPE. SIX VACCINE CANDIDATES ARE UNDERGOING TESTING IN CLINICAL TRIALS IN KENYA, SENEGAL, SOUTH AFRICA, THE UNITED KINGDOM, AND THE UNITED STATES WITH SUPPORT FROM AERAS FOR PROTOCOL DEVELOPMENT, SAFETY MONITORING, REGULATORY AND IMMUNOLOGY. WE ALSO DESIGN AND CONDUCT EPIDEMIOLOGY STUDIES TO ESTIMATE TB PREVALENCE AND/OR INCIDENCE UNDER REAL-WORLD TRIAL CONDITIONS TO INFORM ONGOING STUDIES AND TO ASSESS THE FEASIBILITY OF CONDUCTING LARGE-SCALE CLINICAL TRIALS IN TB AT ADDITIONAL RESEARCH SITES IN TB ENDEMIC COUNTRIES, INCLUDING CHINA. 2828592 AERAS ALSO WORKS TO BUILD RELATIONSHIPS THAT SUPPORT ITS GOAL TO DEVELOP TB VACCINES THROUGH COLLABORATION AT THE GLOBAL AND REGIONAL LEVELS WITH MULTI-LATERAL ORGANIZATIONS SUCH AS THE EUROPEAN UNION, THE EUROPEAN INVESTMENT BANK, AND THE WORLD HEALTH ORGANIZATION, AMONG OTHER TB RESEARCHERS AND VACCINE DEVELOPERS, AS WELL AS WITH DONORS, ADVOCATES AND POLICYMAKERS WHO CAN HELP RAISE AWARENESS AND SUPPORT FOR THIS WORK. AERAS' SCIENTIFIC AND EXTERNAL AFFAIRS DEPARTMENTS ARE CRITICAL TO ADVANCING THESE STRATEGIC PARTNERSHIPS TO ENSURE GLOBAL SUPPORT. 112147 347985 CONTRACT RESOURCE SHARING 112147 347985 29851783 true true false false false false false false false false true false false false true true false true false true true true false false false false false false false true false false false false false false false false false false false false false true true true false false true X 56 0 true 87 true true true true SF HK CH false false false false false false false false X 11 10 false false false false false false false true true false false true true true true true true true true false MD X X DONNA D'AMATO 3015472923 1405 RESEARCH BLVD STE 300 ROCKVILLE MD 20850 LOTA ZOTH CHAIRMAN 1.0 0.0 X 0 0 0 BARRY BLOOM DIRECTOR 1.0 0.0 X 0 0 0 DAVID BLUMBERG DIRECTOR 1.0 0.0 X 0 0 0 JAMES CONNOLLY DIRECTOR 1.0 0.0 X 0 0 0 MARJA ESVELD DIRECTOR 1.0 0.0 X 0 0 0 MARIAN JACOBS DIRECTOR 1.0 0.0 X 0 0 0 MICHEL KAZATCHKINE DIRECTOR 1.0 0.0 X 0 0 0 WAYNE PISANO DIRECTOR 1.0 0.0 X 0 0 0 REGINA RABINOVICH DIRECTOR 1.0 0.0 X 0 0 0 GERD ZETTLMEISSL DIRECTOR 1.0 0.0 X 0 0 0 JEFFREY LIBSON BOARD SECRETARY 1.0 0.0 X 0 0 0 THOMAS EVANS PRESIDENT & CEO THRU FEB 2016 40.0 0.0 X X 114234 0 1962 JACQUELINE SHEA LUCAS CEO 40.0 0.0 X X 455747 0 35935 DANILO CASIMIRO CSO 40.0 0.0 X 345017 0 25066 ANN GINSBERG CMO 40.0 0.0 X 396616 0 20314 LEWIS SCHRAGER VP SCIENTIFIC AFFAIRS 40.0 0.0 X 301794 0 17840 KENNETH WALKER VP VACCINE DISCOVERY 40.0 0.0 X 229941 0 29259 DARA ERCK VP OF EXTERNAL AFFAIRS 40.0 0.0 X 250054 0 18679 DANIEL REZNIKOV CFO 40.0 0.0 X 272479 0 20184 WENDY PENRY CHRO 40.0 0.0 X 235625 0 17574 ROBIN GOLDSTEIN SR DIRECTOR PROGRAM MANAGEMENT 40.0 0.0 X 251183 0 18551 RITA KHANNA GENERAL COUNSEL 40.0 0.0 X 239236 0 16541 MARIA LEMPICKI SR DIRECTOR PROJECT MANAGEMENT 40.0 0.0 X 238931 0 34144 ELLEN WILCOX DIR STRATEGIC COMMUNICATIONS 40.0 0.0 X 225109 0 24590 BARBARA SHEPHERD DIRECTOR MEDICAL WRITING 40.0 0.0 X 211789 0 21912 3767755 0 302551 35 false true false Quintiles Ltd PROFESSIONAL SERVICES CENTRE LIVINGSTON 0 UK EH54 6GA Clinical 2367418 The University of Cape Town WERNER BEIT SOUTH BUILDING CAPE TOWN 0 SF EH54 6GA Clinical 1169298 OREGON HEALTH SCIENCE UNIVERSITY 3181 SW Sam Jackson Park RD PORTLAND OR 97239 Research 3620911 BIOMEDICAL PRIMATE RESEARCH CENTER LANGE KLEIWEG 161 2288 GJ RIJSWIJK 0 NL Research 1144065 UNIVERSITY OF PITTSBURGH 4200 FIFTH AVENUE PITTSBURGH PA 15260 RESEARCH 975459 26 2133425 31256512 33389937 CONTRACT RESOURCE SHARING 541900 347985 347985 347985 14736 14736 0 0 2350193 3587639 -1237446 0 -1237446 -1237446 0 0 0 0 0 0 0 0 0 0 FOREIGN CURRENCY LOSS 900099 -243743 -243743 MISCELLANEOUS REVENUE 900099 181789 181789 -61954 32453258 347985 -1284664 0 0 2308237 2308237 0 2788320 2242457 545863 0 6591930 4800146 1791784 738945 685790 53155 818080 677516 140564 519000 420888 98112 0 607113 72210 534903 159210 159210 0 0 0 0 0 618435 401578 216857 0 0 1513509 1308752 204757 702704 548215 154489 0 122920 102933 19987 0 0 367216 236482 130734 230945 77589 153356 CONTRACT SERVICES 14681490 14325441 356049 COLLABORATION AGREEMENTS 865362 865362 LAB SUPPLIES AND MATERIALS 484162 484162 RECRUITMENT 250300 181878 68422 112147 112147 34480025 29851783 4628242 0 500 500 14146490 10260004 319889 0 43884 675600 0 0 0 0 0 0 0 0 2946881 2417717 27752407 25824527 3219428 1927880 11214126 12481413 0 0 0 0 0 0 758036 682646 32649234 28445760 6550183 4519531 0 0 189859 207845 0 0 0 0 0 0 0 0 0 0 1522892 1448409 8262934 6175785 X 3904939 2640423 20481361 19629552 0 0 24386300 22269975 32649234 28445760 X -2026767 -26522 -63036 X false true X true true true X JOHN HOPKINS BALTIMORE MD ST LOUIS ST LOUIS MO OREGON HEALTH PORTLAND OR ALBERT EINSTEIN COLLEGE OF MEDICINE NEW YORK NY MASSACHUSETTS GENERAL HOSPITAL CONCORD MA UNIVERSITY OF PITTSBURGH PITTSBURGH PA VACCINE RESEARCH CENTER AT NIH BETHESDA MD FRED HUTCHINSON CANCER RESEARCH CENTER SEATTLE WA RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 18822424 17609470 1212954 230839 159683 71156 5759366 5140159 619207 2939778 2915215 24563 1927880 0 DEFERRED RENT 1347481 DEFERRED 457 PLAN 94432 GRANT PAYABLE NON GOV 6496 1448409 X 33711249 -26522 47067 20545 33690704 -1237446 -1237446 32453258 35906247 63036 1363186 1426222 34480025 34480025 FIN 48 FOOTNOTE In accordance with authoritative guidance issued by the FASB, Aeras would recognize a tax liability when, despite management's belief that tax return positions are supportable, management believes that certain positions may not be fully sustained upon review by tax authorities. Liabilities for uncertain tax positions would be measured based upon the largest liability that is greater than 50% likely to be incurred on any settlement with taxing authorities. To the extent that the final tax outcome of these matters would differ from the liabilities recorded, such differences would be included in income tax expense in the period in which such determination is made. Interest and penalties, if any, related to accrued liabilities for potential tax assessments also would be included in income tax expense. Management has evaluated Aeras' tax positions and has concluded that Aeras has taken no material uncertain tax positions that require adjustment to the consolidated financial statements to comply with the provisions of this guidance. Aeras is currently under no income tax examinations in any Federal, or state or local jurisdictions. Aeras is generally no longer subject to income tax examinations by the U.S. federal, state or local tax authorities for years ended December 31, 2012 and prior. PART XI, LINE 2D Income of AffiliateS $ 2,229,564 Eliminations $ (2,182,497) --------------- Total $ 47,067 PART XI, LINE 4B RECLASS RENTAL INCOME $ 2,350,193 RECLASS RENTAL EXPENSES $ (3,587,639) --------------- Total $ (1,237,446) PART XII, Line 2D Expenses of Affiliate $ 2,308,237 Reclassed Rental Income $ (2,350,193) Reclassed Rental Expense $ 3,587,639 Eliminations $ (2,182,497) -------------- Total $ 1,363,186 true Europe (Including Iceland and Greenland) Program Services PRECLINICAL 1822583 Europe (Including Iceland and Greenland) Program Services CLINICAL 2551336 North America Program Services PRECLINICAL 7763 Sub-Saharan Africa 1 20 Program Services CLINICAL 5798998 East Asia and the Pacific 1 4 Program Services PRECLINICAL 351202 2 24 2 24 10531882 10531882 East Asia and the Pacific SEE PART V 394854 EFT Sub-Saharan Africa SEE PART V 1913383 EFT 2 false false true false false false FORM 990, SCHEDULE F, PART I, LINE 2 AERAS RECEIVES A REQUEST FOR SUPPORT. SENIOR MANAGEMENT REVIEWS THE REQUEST THROUGH THE DUE DILIGENCE CRITERIA APPROVED BY THE BOARD AND IMPLEMENTED BY MANAGEMENT. FOR EXAMPLE, THE GRANTEE MUST BE A CHARITY EITHER UNDER US LAW OR UNDER LOCAL LAW. AERAS MAY REQUEST GOVERNANCE DOCUMENTS FROM THE ORGANIZATION, IRS DETERMINATION LETTER (OR LOCAL EQUIVALENT) INDICATING IT IS A CHARITY, LISTS OF EXECUTIVE STAFF AND BOARD MEMBERS, AND FINANCIAL STATEMENTS OF THE REQUESTOR. UPON MANAGEMENT APPROVAL, FUNDS ARE SENT TO THE REQUESTING ORGANIZATION. COPIES OF THE REQUEST AND PAYMENT ARE MAINTAINED AT AERAS. FORM 990, SCHEDULE F, PART II, COLUMN (D) The purpose of the grant is to provide support to Clinical and Preclinical projects such as MTBVAC, HBHA VPM, UOX and ChAd. X X true true X X X X X true false false false false false false false false DANILO CASIMIRO CSO 318729 0 0 0 26288 0 9173 0 15893 0 370083 0 0 0 ANN GINSBERG CMO 368116 0 28500 0 0 0 15900 0 4414 0 416930 0 0 0 JACQUELINE SHEA LUCAS CEO 402532 0 53215 0 0 0 15900 0 20035 0 491682 0 0 0 LEWIS SCHRAGER VP SCIENTIFIC AFFAIRS 255094 0 5000 0 41700 0 13562 0 4278 0 319634 0 0 0 KENNETH WALKER VP VACCINE DISCOVERY 228941 0 1000 0 0 0 13326 0 15933 0 259200 0 0 0 DARA ERCK VP OF EXTERNAL AFFAIRS 248054 0 2000 0 0 0 14613 0 4066 0 268733 0 0 0 DANIEL REZNIKOV CFO 267479 0 5000 0 0 0 15845 0 4339 0 292663 0 0 0 WENDY PENRY CHRO 230625 0 5000 0 0 0 13561 0 4013 0 253199 0 0 0 ROBIN GOLDSTEIN SR DIRECTOR PROGRAM MANAGEMENT 248683 0 2500 0 0 0 13997 0 4554 0 269734 0 0 0 RITA KHANNA GENERAL COUNSEL 236736 0 2500 0 0 0 12394 0 4147 0 255777 0 0 0 MARIA LEMPICKI SR DIRECTOR PROJECT MANAGEMENT 237550 0 1381 0 0 0 14319 0 19825 0 273075 0 0 0 ELLEN WILCOX DIR STRATEGIC COMMUNICATIONS 187522 0 5835 0 31752 0 10325 0 14265 0 249699 0 0 0 BARBARA SHEPHERD DIRECTOR MEDICAL WRITING 208789 0 3000 0 0 0 12326 0 9586 0 233701 0 0 0 SCHEDULE J, PART I, LINE 4A - SEVERANCE LEWIS SCHRAGER $ 41,700 ELLEN WILCOX $ 31,752 FORM 990, PART VI, LINE 11B A draft version of the Form 990 is shared with the Board of Directors of Aeras and once approved it is filed with the IRS. FORM 990, PART VI, LINE 12C Aeras' policy is written to protect Aeras' interest when it is contemplating entering into a transaction or arrangement that might benefit the private interest of directors, committee members, officers, employees and retained consultants of Aeras. In connection with any actual or possible conflicts of interest, an interested person must disclose the existence of his or her interest and all material facts to the directors and members of the committee with board-delegated powers considering the proposed transaction or arrangement. After disclosure of all material facts and discussion with the person, the person shall leave the board or committee meeting while their determination of a conflict of interest is discussed and voted upon. The remaining board or committee members shall decide if a conflict of interest exists. FORM 990, PART VI, LINE 15 Aeras has a Compensation Committee which determines the CEO compensation level based on his responsibilities, size of the organization, funding levels and organization objectives. Compensation is based on comparability data, is approved by independent Board members, and the process is documented in the Board minutes. Compensation for other officers is determined by the CEO, based on the officer's responsibilities, funding levels and organization objectives. compensation is based on comparability data and is shared with independent board members. FORM 990, PART VI, LINE 19 Governing documents, including Articles of Incorporation, Bylaws, Board minutes, Conflict of Interest policy and financial statements are available upon request. FORM 990, PART XI, LINE 9 OTHER CHANGES IN NET ASSETS (102,023) - RESTRICTION CLASSIFICATION ADJUSTMENT TO NET ASSETS AERAS SOUTH AFRICA BLACKRIVER PARK 1ST FLR CAPE TOWN OBSERVATORY SF 7925 CLINICAL TR SF N/A N/A NA true AERAS HONG KONG UNIT 1618 16/F MIRAMAR TOWER KOWLOON HK Holding Compa HK Aeras C Corp -21266 394390 1.00000 true Aeras Beijing Biological Tech Co Ltd Unit 1446 14F A Tower Pacific Beijing CH Consulting CH Aeras Hong Kong C Corp 39193 203980 1.00000 true false false false false false false false false false false false false false true false false false false false Aeras South Africa N 1761017 Cash Aeras Beijing Biological Tech Co Ltd N 315520 Cash